This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by BRAVO, E. L. Articles by TARAZI, R. C. Search for Related Content PubMed PubMed Citation Articles by BRAVO, E. L. Articles by TARAZI, R. C.

(Circulation. 1973;48:491.)
© 1973 American Heart Association, Inc.

---

Spironolactone as a Nonspecific Treatment for Primary Aldosteronism

EMMANUEL L. BRAVO M.D.¹; HARRIET P. DUSTAN M.D.¹; ROBERT C. TARAZI M.D.¹

¹ From the Research Division, The Cleveland Clinic Foundation and The Cleveland Clinic Educational Foundation, Cleveland, Ohio.

Studies were carried out in 14 patients with primary aldosteronism (1°A) to examine the mechanism(s) by which spironolactone reduces arterial pressure. Measures that produced salt and water depletion were found to consistently reduce arterial pressure. Plasma volume and arterial pressure correlated directly and significantly, r = +0.509 (P < 0.001), whether pressure was reduced by spironolactone alone or combined with either hydrochlorothiazide or low dietary sodium, or by rapid sodium depletion alone. With small doses of spironolactone, restricting or liberalizing dietary sodium was associated with decreases or increases, respectively, in arterial pressure and plasma volume.

These results suggest 1) that the antihypertensive action of spironolactone is nonspecific and largely dependent on salt and water balance and 2) that maintenance of reduced plasma volume or extracellular fluid volume (ECFV) is a basic component of the pressure response of 1°A to spironolactone therapy.

Key Words: Plasma volume • Primary hypertension • Extracellular fluid volume expansion • Diuretics • Dietary salt intake

Submitted on April 3, 1973
Accepted on May 8, 1973